Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability of ragweed allergy immunotherapy in patients with allergic rhinoconjunctivitis

Trial Profile

Tolerability of ragweed allergy immunotherapy in patients with allergic rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 27 Feb 2013 New trial record
    • 22 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top